Evaluating VC004 for patients with advanced solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase III clinical trial designed to assess the safety and efficacy of VC004 capsules in patients suffering from locally advanced or metastatic solid tumors. The study is a single-arm, open-label trial conducted across multiple centers, allowing for a diverse patient population. Participants will receive VC004 and will be monitored for treatment outcomes and side effects. The trial aims to provide valuable data on the effectiveness of this intervention in a challenging patient group.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* All subjects or legal representatives are willing and able to sign ICF approved by the ethics committee before starting any screening procedures；
* Male or female, age ≥12 years old;

Exclusion Criteria:

* Patients have undergone major surgery within 4 weeks prior to the first dose or are expected to undergo major surgery during the trial (excluding vascular access establishment procedures, biopsy procedures);
* Adverse reactions caused by previous treatment have not recovered to ≤1 grade (evaluated by the investigator);
* Patients had been treated with a strong CYP3A inhibitor or inducer within 7 days prior to the first administration of the study drug.

Where it's running

• Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Principal investigator: yuankai Shi — Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College
• Study coordinator: xiaojuan Lai
• Email: lai_xiaojuan@vcarepharmatech.com
• Phone: 15358160458

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• 5-Azacitidine with PD-1/PD-L1 Inhibitor in PD-1/PD-L1 Refractory Tumors

  This phase I study tests different doses of 5-azacitidine combined with a PD-1/PD-L1 blocker to see if the combo can help patients whose tumors no longer respond to PD-1/PD-L1 therapy.

  Recruiting Phase 1 University of Iowa · Iowa City, Iowa · NCT07404332

• Safety and anti-tumor activity of IPN60300 in adults with advanced or metastatic solid tumors

  This trial will test whether injections of IPN60300 are safe and can help control advanced or metastatic solid tumors in adults.

  Recruiting at 10 sites Phase 1/2 Ipsen · New Haven, Connecticut and 11 other locations · NCT07213817

• YH32364 for locally advanced or metastatic EGFR‑overexpressing solid tumors

  This trial will test whether YH32364 can help adults with advanced or metastatic cancers that overexpress EGFR when other treatments haven't worked.

  Recruiting at 4 sites Phase 1/2 Yuhan Corporation · Seoul and 3 other locations · NCT06975410

• Imaging of immune response in advanced solid tumors

  This study is testing a new imaging method to see how well it can track the immune response in people with advanced solid tumors who are receiving PD-1 antibody treatments.

  Recruiting at 2 sites Phase 2 University Medical Center Groningen · Amsterdam and 3 other locations · NCT06534190

• Evaluating NVL-330 for advanced HER2-altered lung cancer

  This study is testing a new treatment called NVL-330 to see if it can safely help people with advanced lung cancer that has changes in the HER2 gene.

  Recruiting at 20 sites Phase 1 Nuvalent Inc. · Irvine, California and 20 other locations · NCT06521554

• Lattice radiation therapy for treating large tumors

  This study is testing a new type of radiation therapy called lattice radiation therapy to see if it works better than standard treatment for people with large tumors.

  Recruiting Phase 2 University of Cincinnati · Cincinnati, Ohio · NCT06416007

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.